Yunsheng Yang | Inflammatory Bowel Disease | Best Researcher Award

Posted on by Pencis

Prof. Dr. Yunsheng Yang | Inflammatory Bowel Disease | Best Researcher Award

The First Medical Center, Chinese PLA General Hospital | China

AUTHOR PROFILE

ORCID ID

🌟YUNSHENG YANG, M.D. – A LEADER IN GASTROENTEROLOGY 🏥

🎓EARLY ACADEMIC PURSUITS 

Dr. Yunsheng Yang earned his M.D. from the First Military Medical University in 1995, laying the foundation for his illustrious medical career. He pursued postdoctoral training at the Fourth Military Medical University in China, further honing his expertise in gastroenterology. His academic journey extended internationally with visiting scholar positions at the University of Sydney’s Westmead Hospital in 2008 and Mayo Clinic Rochester in 2014, where he gained invaluable global exposure to advanced medical practices.

👩‍🏢PROFESSIONAL ENDEAVORS 

Currently, Dr. Yang serves as the Academic Director of the Department of Gastroenterology and Hepatology at the First Medical Center, Chinese PLA General Hospital (PLAGH, 301 Hospital) in Beijing, China. His leadership extends beyond national borders, with visiting or adjunct professorships at Shenzhen University, Universitas Amoiensis, and the University of Michigan, USA.

His involvement in prestigious medical societies includes being the immediate past president of the Chinese Society of Gastroenterology and the Director of the APSDE Training Center in PLAGH since 2006. Dr. Yang actively engages with the World Gastroenterology Organization (WGO), serving as a scientific committee member and having previously contributed to the WGO Endoscopy Group and Nomination Committee.

🔬CONTRIBUTIONS AND RESEARCH FOCUS 

Dr. Yang’s clinical expertise primarily revolves around gastrointestinal (GI) disorders and therapeutic Endoscopic Retrograde Cholangiopancreatography (ERCP). His research is focused on robot-assisted endoscopy and GI microbiota, where he has pioneered multiple innovative procedures in China, including:

  • Endoscopic suturing for GERD (2001)
  • Double balloon enteroscopy (2003)
  • Peroral video cholangioscopy and laser lithotripsy (2004)
  • Confocal endomicroscopy (2006)
  • MUSE for GERD (2017)
  • Fecal Microbiota Transplantation (FMT) clinical trials for IBD, autism, and Tourette syndrome (since 2014)

Notably, he led the development of the YunSRobot, a robot-assisted GI endoscopy system, successfully performing gastroscopy on human volunteers in 2017 and completing remote gastroscopy in 2021. These groundbreaking achievements have been published and indexed in PubMed.

📚IMPACT AND INFLUENCE 

Dr. Yang’s influence in the field of gastroenterology is reflected in his extensive publication record. He has authored over 200 articles in Chinese journals and more than 150 papers in international SCI-indexed journals, including prestigious titles such as Gastroenterology, Hepatology, The American Journal of Gastroenterology (AJG), Gastrointestinal Endoscopy (GIE), Alimentary Pharmacology & Therapeutics (AP&T), and Gut.

As an editorial board member for Gut and AP&T, and associate editor for MMR and JDD, he continues to shape the direction of gastroenterology research and clinical practice worldwide.

🌟ACADEMIC CITES AND RECOGNITION 

Dr. Yang’s research contributions have been extensively cited by peers in the medical and scientific communities. His innovations in endoscopic procedures and gastrointestinal microbiota research have influenced treatment protocols and technological advancements in digestive health worldwide. His pioneering work on FMT for neurological conditions and robotic-assisted endoscopy is setting new standards in precision medicine.

💪LEGACY AND FUTURE CONTRIBUTIONS 

Dr. Yang’s enduring legacy lies in his transformative impact on gastroenterology, blending cutting-edge technology with clinical expertise. His leadership in developing robotic-assisted endoscopy has the potential to revolutionize non-invasive diagnostics and treatment, paving the way for AI-integrated endoscopic procedures.

Looking ahead, Dr. Yang continues to push the boundaries of GI research, particularly in the integration of robotics, microbiota-based therapies, and novel endoscopic interventions. His mentorship of young gastroenterologists ensures a lasting impact on the field, fostering the next generation of leaders in digestive health research and clinical innovation.

🌍CONCLUSION 

Dr. Yunsheng Yang stands as a trailblazer in the field of gastroenterology, with his extensive contributions in clinical practice, research, and technological innovation. His groundbreaking advancements in robot-assisted endoscopy and GI microbiota research have set new benchmarks in the medical field. His dedication to patient care, scientific discovery, and mentorship ensures his influence will resonate for years to come, shaping the future of digestive health worldwide.

 

📊🔬NOTABLE PUBLICATION:
  1. Title: Fecal microbiota transplantation significantly improved respiratory failure of amyotrophic lateral sclerosis.
    Authors: Yan J, Chen H, Zhang Y, Peng L, Wang Z, Lan X, Yu S, Yang Y.
    Year: 2024

 

  1. Title: Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication.
    Authors: Chen J, Zhang Y, Min H, Zhi J, Ma S, Dong H, Yan J, Chi X, Zhang X, Yang Y.
    Year: 2024

 

  1. Title: Colorectal cancer and gut microbiota studies in China.
    Authors: Wang Z, Dan W, Zhang N, Fang J, Yang Y.
    Year: 2023

 

  1. Title: The fecal microbiota from children with autism impact gut metabolism and learning and memory abilities of honeybees.
    Authors: Li Y, Zhang Y, Luo X, Meng Y, Zhong Z, Zheng H, Yang Y.
    Year: 2023

 

  1. Title: Deep insights into the gut microbial community of extreme longevity in South Chinese centenarians by ultra-deep metagenomics and large-scale culturomics.
    Authors: Li C, Luan Z, Zhao Y, Chen J, Yang Y, Wang C, Jing Y, Qi S, Li Z, Guo H, et al.
    Year: 2022

Guohua Yang | Medical Genetics | Best Researcher Award

Posted on by Pencis

Assoc. Prof. Dr. Guohua Yang | Medical Genetics | Best Researcher Award

Wuhan University | China

Author Profile

ORCID ID

🔬🧬 Prof. Guohua Yang – Associate Professor, Wuhan University

Expert in Medical Genetics & Precision Medicine

🏛️ Institution: Wuhan University
🎓 Academic Focus: Medical Genetics, Gene Mutation & Disease Mechanisms

🔍 Research Interests:

  • 🧬 Gene Mutations & Genetic Diseases – Understanding the functional impact of genetic variations.
  • 🏥 Innovative Gene Diagnosis – Developing cutting-edge diagnostic methods for hereditary conditions.
  • 🦠 Hepatocellular Carcinoma – Investigating molecular mechanisms and drug discovery strategies.

📌 Leadership & Professional Roles:

  • 👨‍⚕️ Chairman, Gene Health Branch, Hubei Genetic Society
  • 🏥 Standing Committee Member, Reproductive Genetics Branch, Hubei Reproductive Health Society
  • 🧑‍⚕️ Member, Medical Genetics Branch, Hubei Medical Association
  • 👶 Committee Member, Fertility Protection & Restoration, China Association for Healthy Children
  • 🏥 Deputy Director, Precision Medicine Committee, Zhongguancun Cancer Minimally Invasive Treatment Alliance

📚 Editorial Appointments:

  • ✍️ Guest Editor, Frontiers in Genetics (Monogenic Diseases Column)
  • 📖 Editorial Board Member, Spandidos Journal, Brain Research

🏆CONCLUSION 

Prof. Guohua Yang is a leading expert in medical genetics and precision medicine, making significant contributions to gene mutation research, innovative genetic diagnostics, and hepatocellular carcinoma treatment. As a key figure in multiple academic and professional organizations, his leadership and editorial roles further strengthen his impact in the field. His dedication to advancing genetic research and clinical applications continues to shape the future of genomic medicine and personalized healthcare. 🏥🧬

 

📊🔬NOTABLE PUBLICATION:
  • Title: Clinic Examination and Gene Diagnosis for a Birt–Hogg–Dubé Syndrome Family With a Novel FLCN Frameshift Mutation Causing Nonsense‐Mediated mRNA Degradation.
    Authors:     Yang Xu, Jie Gao, Yang An, Chenxi Zou, Guoqing Ding, Guohua Yang, Finlay Macrae.
    Journal: Human Mutation
    Year: 2025

 

  • Title: A Novel TSC1 Frameshift Mutation c.1550_1551del Causes Tuberous Sclerosis Complex by Aberrant Splicing and Nonsense‐Mediated mRNA Degradation (NMD) Simultaneously in a Chinese Family.
    Authors:     Cong Qiu, Chengyan Li, Xiaoyun Tong, Luoyang Dai, Wenda Liu, Yulie Xie, Qimei Zhang, Guohua Yang, Tao Li.
    Journal: Molecular Genetics & Genomic Medicine
    Year: 2020

 

  • Title: Identification and Interaction Analysis of Significant Genes and MicroRNAs in Pterygium.
    Authors:     Siying He, Hui Sun, Yifang Huang, Shiqi Dong, Chen Qiao, Shuai Zhang, Chen Wang, Fang Zheng, Ming Yan, Guohua Yang.
    Journal: BioMed Research International
    Year: 2019

Prof. Xinyan Zhao | Liver Injury | Best Researcher Award

Posted on by Pencis

Prof. Xinyan Zhao | Liver Injury | Best Researcher Award

Beijing Friendship Hospital, Capital Medical University | China

Author Profile

Scopus

Google Scholar

Biography of Xin Yan Zhao, M.D., Ph.D. 🌟🩺

Professor of Medicine | Head of Liver Research Center | Expert in Hepatology

Dr. Xin Yan Zhao is a distinguished Professor of Medicine and the Head of the Liver Research Center at Beijing Friendship Hospital, Capital Medical University, Beijing, China. She is also affiliated with the National Clinical Research Center for Digestive Disease, where she leads groundbreaking research in hepatology and liver transplantation pathology.

🎓 Education

  • M.D. (1995–2000)
    Clinical Medicine, Capital Medical University, Beijing, China
  • M.S. (2000–2003)
    Internal Medicine, Capital Medical University, Beijing, China
  • Ph.D. (2005–2008)
    Hepatology, Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China

👩‍⚕️ Professional Experience

  • Head of Liver Research Center (2022–Present)
    Beijing Friendship Hospital, Capital Medical University
  • Hepatologist & Clinical Liver Pathologist (2016–2022)
    Beijing Friendship Hospital, Capital Medical University
  • Visiting Scholar (2015–2016)
    Department of Liver and Transplant Pathology, University of Pittsburgh Medical Center, USA
  • Associate Professor (2014–2015)
    Beijing Friendship Hospital, Capital Medical University
  • Attending Doctor, Department of Hepatology (2009–2014)
    Beijing Friendship Hospital, Capital Medical University
  • Chief Resident of Internal Medicine (2008)
    Beijing Friendship Hospital, Capital Medical University
  • Resident of Internal Medicine (2003–2007)
    Beijing Friendship Hospital, Capital Medical University

🏆 Awards and Honors

  • 2006: Excellent Paper Presentation Award, Chinese Society of Hepatology
  • 2008, 2010, 2013: Excellence in Teaching Award, Beijing Friendship Hospital
  • 2010: Award for Teaching Presentation and Skills in English, Capital Medical University
  • 2014: Excellent Young Investigator Award, APASL College, Beijing
  • 2018: Excellent Paper Presentation Award, Beijing Digestive Disease Weekend

🌐 Roles in Professional Societies

  1. Chairman (2024–2025), Pathology Committee, International Liver Transplantation Society 🌍
  2. Committee Member, Autoimmune Hepatitis Cooperation Group, Chinese Society of Hepatology
  3. Committee Member, Transplantation Pathology, Chinese Medical Doctor Association
  4. Committee Member, Digestive Pathology Cooperation Group, Chinese Society of Digestive Diseases

🌏 CONCLUSION

Dr. Xin Yan Zhao exemplifies excellence in medicine, research, and education. As a globally recognized leader in hepatology and liver transplantation pathology, she continues to drive innovation and collaboration in the field. Her dedication to advancing medical knowledge, training the next generation of physicians, and contributing to professional societies underscores her significant impact on liver research and clinical practice worldwide. 🌟🩺

📊🔬NOTABLE PUBLICATION:
  • Peridroplet mitochondria are associated with the severity of MASLD and the prevention of MASLD by diethyldithiocarbamate
    • Authors: Sun, X.; Yu, Q.; Qi, Y.; Cong, M.; Liu, T.
    • Journal: Journal of Lipid Research
    • Year: 2024

 

  • Autoimmune hepatitis with confluent necrosis indicates severe liver injury but responds well to standard immunosuppressive therapy
    • Authors: Sun, X.; Su, Y.; Wee, A.; Zhao, X.; Jia, J.
    • Journal: Histology and Histopathology
    • Year: 2024

 

  • Prevalence and clinical profiles of primary sclerosing cholangitis in China: Data from electronic medical records and systematic literature retrieval
    • Authors: Xu, X.; Meng, T.; Shi, L.; Jia, J.; Kong, Y.
    • Journal: Journal of Autoimmunity
    • Year: 2024

 

  • Multiscale X-ray phase-contrast CT uncovers adaptive changes and compensatory mechanisms of circulatory pathways during acute liver injury
    • Authors: Zhao, Y.; Lv, W.; He, Y.; Hu, C.; Jian, J.
    • Journal: Communications Biology
    • Year: 2024

 

  • Multiple Low-Level Viraemia Suggest Hindered Liver Fibrosis Regression in Chronic Hepatitis B Patients During Antiviral Therapy
    • Authors: Lu, Z.; Sun, Y.-M.; Chen, S.; Zhao, X.; You, H.
    • Journal: Journal of Viral Hepatitis
    • Year: 2024

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award

Posted on by Pencis

Assist Prof Dr Matthias Bartneck | Cancer Therapy | Best Researcher Award 

RWTH Aachen University | Germany

AUTHOR PROFILE

Scopus

Google Scholar

Orcid ID

EARLY ACADEMIC PURSUITS

Priv.-Doz. Dr. rer. nat. Matthias Bartneck embarked on his academic journey with a diploma in Biology from the University of Bielefeld (2001-2006). His diploma thesis focused on gene expression and metabolite profiling of human primary mamma carcinomas, under the supervision of Dr. Anke Becker. He continued his academic pursuits with a Doctor of Natural Sciences degree from RWTH Aachen (2007-2010), where his research centered on the interactions of human primary immune cells with various nanomaterials. This work was supervised by Prof. Gabriele Zwadlo-Klarwasser.

PROFESSIONAL ENDEAVORS

Dr. Bartneck’s professional career has been marked by a series of significant positions and collaborations. He has been employed at the Medical Faculty 10, Gastroenterology, and Faculty 1 Leibniz Institute for Interactive Materials DWI/RWTH Institute for Technical and Macromolecular Chemistry (ITMC) since 2023. He has also served as a guest lecturer at the Max Planck Research Training School Matter to Life. From 2018 to 2022, he was a lecturer at the Center for Functional Magnetic Materials, Immanuel Kant Baltic Federal University in Kaliningrad, Russia. Additionally, Dr. Bartneck has been a group leader at the Medical Faculty, Medical Clinic III, RWTH Aachen since 2014, focusing on immunomodulatory nanomedicine for inflammatory diseases and cancer.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER THERAPY

Dr. Bartneck’s research has significantly advanced the fields of gastroenterology, hepatology, and nanomedicine. His work has delved into the development of novel nanocarriers for treating liver diseases and cancer, as well as the modulation of immune cell migration and activation in inflammatory diseases. His research has been supported by substantial funding, including grants from the German Research Foundation (DFG) and the Wilhelm Sander Foundation. His contributions include over 61 publications, 18 as the first author and 4 as the last author, along with 7 book chapters and 9 reviews.

CITATIONS

  • Zitate           4439
  • h-index        35
  • i10-index     49

IMPACT AND INFLUENCE

Dr. Bartneck’s research has had a profound impact on the scientific community, evidenced by a total of 3764 citations and an H-index of 32. His expertise in immunomodulatory nanomedicine has led to collaborations with prestigious institutions and industry partners, including Bayer Healthcare, Novartis, and Precision Nanosystems. His work has been recognized with several fellowships and awards, such as the Young Investigator Award from the European Association for the Study of the Liver (EASL).

ACADEMIC CITES

Dr. Bartneck has held numerous academic positions and provided significant contributions to teaching and mentoring. He has supervised a wide range of students, from bachelor to doctoral levels, across multiple disciplines including medicine, chemistry, and biology. His teaching roles have included lectures and practical courses in materials science, blood and defense, and inflammation at RWTH Aachen.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Bartneck’s legacy is marked by his interdisciplinary approach and dedication to advancing nanomedicine and immunology. He has secured research funds exceeding €1,500,000 in 2022 alone for the development of novel lipid-based nucleic acid therapeutics. His future contributions are expected to further enhance the understanding and treatment of inflammation-associated diseases and cancer. His continued collaborations with international academic and industry partners underscore his commitment to advancing scientific knowledge and innovation.

NOTABLE PUBLICATION:

Citation: 08         Year: 2022

Citation: 01        Year: 2023

 

Excellence in Translational Medicine in Oncology Award

Posted on by Pencis

Introduction: Welcome to the pinnacle of innovation in healthcare! The Excellence in Translational Medicine in Oncology Award is a beacon for those pushing the boundaries of research and clinical application in the fight against cancer. Join us in recognizing and celebrating the visionaries shaping the future of translational medicine.

Award Eligibility: Open to global medical professionals and researchers, this award has no age limits. To qualify, candidates must hold a doctoral degree, showcase significant contributions to translational medicine in oncology, and have a noteworthy publication record in reputable journals.

Evaluation Criteria: Candidates will be evaluated on the transformative impact of their translational research, the quality and relevance of publications, and their contributions to bridging the gap between laboratory discoveries and clinical applications in oncology.

Submission Guidelines: Entrants must submit a comprehensive package including a detailed biography, an abstract of their translational research, and supporting files. Adherence to specified format guidelines is crucial for a fair evaluation process.

Recognition and Community Impact: The award not only honors individual excellence but also acknowledges the broader impact of the recipient's work on the oncology community and patient care. Awardees will be recognized at prominent events, amplifying the reach and influence of their translational endeavors.

Drug Design and Clinical Trials

Posted on by Pencis

Drug Design and Clinical Trials

 

Introduction: Drug Design and Clinical Trials

The field of drug design and clinical trials represents a crucial bridge between scientific innovation and the improvement of human health. It encompasses the intricate processes involved in developing new pharmaceutical agents, assessing their safety and efficacy, and ultimately bringing them to the patients who need them. This dynamic and collaborative field plays a pivotal role in advancing medical treatments and therapeutics for a wide range of diseases and conditions.

Subtopics:

Rational Drug Design: Rational drug design involves the targeted creation of new drugs based on a deep understanding of the biological mechanisms underlying diseases. This subtopic explores the principles and techniques used in designing drugs with enhanced specificity and effectiveness.

Preclinical Testing: Before advancing to human trials, potential drug candidates undergo rigorous preclinical testing. This subtopic discusses the various stages of preclinical testing, including in vitro and animal studies, to evaluate safety and efficacy.

Clinical Trial Phases: Clinical trials are divided into phases, each serving a distinct purpose. This subtopic outlines the different phases (Phase I, II, III, and IV) of clinical trials, highlighting their objectives and the types of participants involved.

Patient Recruitment and Informed Consent: The recruitment of participants and obtaining informed consent are critical ethical aspects of clinical trials. This subtopic explores the importance of ethical considerations, participant rights, and the informed consent process in clinical research.

Data Analysis and Regulatory Approval: After the completion of clinical trials, data analysis and regulatory approval processes determine the fate of a drug candidate. This subtopic delves into the statistical methodologies used to analyze trial data and the regulatory agencies responsible for approving new drugs for market release.